相关实验视频
Updated: Jan 8, 2026

08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
10.3K
与抗瘤剂相关的心脏毒性:基于FDA不良事件报告系统的药监测研究
Xiaohan Qiu1, Qinxiao Li2, Yiyin Rong2
1Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Therapeutic advances in drug safety
|December 15, 2025
概括
这项研究使用FDA数据分析了癌症药物的副作用,揭示了不同疗法的独特心脏风险. 它强调了针对诸如环素和免疫检查点抑制剂等药物的特定监测时间,以提高患者安全.
科学领域:
- 心脏瘤学 - 心脏瘤学
- 药物监督 药物监督 药物监督
- 药物安全 药物安全
背景情况:
- 心血管不良事件是抗瘤治疗的关键并发症,影响癌症存活率.
- 对于现代癌症疗法中的心脏毒性概况,药物监测数据有限.
研究的目的:
- 系统地分析与抗瘤剂相关的心脏毒性模式.
- 使用FDA不良事件报告系统 (FAERS) 数据,为基于证据的心血管监测策略提供信息.
主要方法:
- 使用不成比例性分析 (ROR,PRR) 和时间到发病评估的回顾性药监测研究.
- 对2004-2024年FAERS数据的分析,确定药物事件关联和时间模式.
主要成果:
- 在18,289,374份报告中,确定了51,402例与抗原瘤相关的心血管毒性病例.
- 揭示了不同的特定类型的模式:人环素 (结构损伤),免疫检查点抑制剂 (心肌炎) 和胺 (血管).
- 证明了关键的时间模式:早期发病的皮里米丁,中间的 antracyclines,和延迟的线粒激素. 心脏性休克的死亡率为43.08%.
结论:
- 这项研究揭示了抗瘤性心脏毒性的非特征性的时间和机制模式.
- 为心血管监测提供了基于证据的框架,强调了特定药物类别的关键干预窗口.
- 支持开发风险分层心脏瘤学协议,以治疗类量身定制.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.7K
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Therapeutic Drug Monitoring: Affecting Factors
175
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
175
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K

